STOCK TITAN

State Street discloses 5.1% Celldex (CLDX) ownership stake filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Celldex Therapeutics, Inc. common stock. As of 12/31/2025, State Street reported beneficial ownership of 3,397,713 shares, representing 5.1% of Celldex’s outstanding common stock.

State Street reported shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares, with no sole voting or dispositive authority. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Celldex.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:02/09/2026

FAQ

What ownership stake did State Street report in Celldex (CLDX)?

State Street reported beneficial ownership of 3,397,713 Celldex common shares, representing 5.1% of the class as of 12/31/2025. This crosses the 5% threshold that requires a Schedule 13G disclosure with the SEC.

Does State Street have voting power over Celldex (CLDX) shares?

State Street reported no sole voting power and shared voting power over 3,194,178 Celldex shares. It also reported shared dispositive power, reflecting its role across affiliated investment management entities handling these holdings.

Is State Street’s Celldex (CLDX) stake considered passive or activist?

The Schedule 13G certification states the Celldex securities were acquired and are held in the ordinary course of business and not for changing or influencing control. This language characterizes State Street’s position as a passive institutional holding.

Which State Street affiliates are associated with the Celldex (CLDX) holdings?

The filing lists several investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company as entities connected to the reported beneficial ownership.

Why did State Street have to file a Schedule 13G for Celldex (CLDX)?

Schedule 13G is required when an investor exceeds 5% beneficial ownership of a registered class of equity securities. State Street reported owning 5.1% of Celldex common stock as of 12/31/2025, triggering this beneficial ownership disclosure requirement.
Celldex Therapeutics Inc

NASDAQ:CLDX

CLDX Rankings

CLDX Latest News

CLDX Latest SEC Filings

CLDX Stock Data

1.58B
66.25M
0.19%
111.33%
10.86%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
HAMPTON